Satsuma Pharmaceuticals has registered an initial public offering, seeking to raise $75 million, according to a regulatory filing.
The South San Francisco-based company is working on STS101, a nasal powder version of dihydroergotamine for migraine. It intends to use the money to fund its Phase 3 safety and efficacy clinical trials for STS101, manufacturing costs, preparation for the product’s commercial launch and for working capital and general corporate purposes.
Get the full story on our sister site, Drug Delivery Business News.